The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
XPO1 inhibition as a clinically viable strategy to enhance durability of response to KRASG12D inhibitor in pancreatic ductal adenocarcinoma.
 
Mohammed Najeeb Al Hallak
Speakers' Bureau - AstraZeneca; Guardant Health; Ipsen; Seagen; Takeda
 
Husain Khan
No Relationships to Disclose
 
Amro Aboukameel
No Relationships to Disclose
 
Sahar Bannoura
No Relationships to Disclose
 
Khalil Choucair
No Relationships to Disclose
 
Eliza Beal
No Relationships to Disclose
 
Miguel Tobon
Travel, Accommodations, Expenses - Intuitive Surgical
 
Rafic Beydoun
No Relationships to Disclose
 
Anthony Shields
Consulting or Advisory Role - Caris Life Sciences; Cogent Biosciences; ImaginAb; Legend Biotech
Speakers' Bureau - Caris Life Sciences
Research Funding - Abbisko Therapeutics (Inst); Alkermes; Amal Therapeutics (Inst); Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; Gritstone Bio (Inst); H3 Biomedicine; Halozyme; Hutchison China Meditech; IconOVir Bio (Inst); ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Nuvation Bio (Inst); Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Sorrento Therapeutics (Inst); SQZ Biotechnology (Inst); Taiho Pharmaceutical; Telix Pharmaceuticals; TopAlliance BioSciences Inc (Inst); Torque (Inst); Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Ramzi Mohammad
No Relationships to Disclose
 
Jennifer Beebe-Dimmer
No Relationships to Disclose
 
Philip Philip
Honoraria - Astellas Pharma; Bayer; BioNTech SE; incyte; Ipsen; Novocure; Seagen; SERVIER; Taiho Pharmaceutical; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Incyte
Research Funding - Bayer (Inst); BioNTech SE (Inst); Genentech (Inst); halozyme (Inst); incyte (Inst); Lilly (Inst); Merck (Inst); merus (Inst); novartis (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals
 
Boris Pasche
Employment - TheraBionic
Leadership - TheraBionic (I)
Stock and Other Ownership Interests - TheraBionic
Honoraria - TheraBionic
Consulting or Advisory Role - TheraBionic
 
Asfar Azmi
Consulting or Advisory Role - Gerson Lehrman Group; Guidepoint Inc
Research Funding - Blackstone Therapeutics; Colorado chromatography; FanWave; Purple Biotech